Loading…
Loading grant details…
| Funder | NATIONAL CANCER INSTITUTE |
|---|---|
| Recipient Organization | Oncospace, Inc. |
| Country | United States |
| Start Date | Aug 10, 2023 |
| End Date | Aug 09, 2024 |
| Duration | 365 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | NIH (US) |
| Grant ID | 10932644 |
The goal of this proposal is to create a medical device development tool (MDDT) for use during performance evaluation of artificial intelligence (AI)-based radiotherapy software.
The MDDT is intended to be used by manufacturers during external validation, whereby AI models are tested for generalizability.
Test results can be used for pre-market submissions to the Food and Drug Administation (FDA) and post-market surveillance. The role of the MDDT is to standardize test datasets consisting of tens or hundreds of radiotherapy treatment plans.
Functionality includes: making contoured structure names comply with American Association of Physicists in Medicine (AAPM) Task Group 263 (TG-263) nomenclature, making plan information searchable, and creation of test cohorts. The MDDT will be cloud-based, employing Microsoft Azure Health Data services.
Uploaded treatment plans, and derived information such as standardized names, will be stored using HL-7 Fast Healthcare Interperability Resources (FHIR) and Digital Imaging and Communications in Medicine (DICOM).
The specific aims of this Phase I project are to design and implement the data communication, data storage, and user interface elements of the MDDT, to carry out a pilot usability study, and to create a qualification plan detailing steps to qualify the tool within the FDA MDDT program.
Oncospace, Inc.
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant